One of the smaller details of Trumpcare, the redacted version of Obamacare, is the elimination of a tax imposed on manufacturers of medical devices. While the fate of pre-existing conditions has been hogging the spotlight in recent days, this particular tax and its future could have an impact on companies like Ventripoint Diagnostics (OTCMKTS: VPTDF TSE:VPT), and other small cap biotech....More>>>
Related ARGT Some Positive Indexing News For A Frontier Markets ETF Argentina's Finance Secretary To Meet With Holdouts About Defaulted Bonds
Alright, alright. Argentine footballer Lionel Messi is awesome, too. Awards and statistics and mind-blowing....More>>>
Healthcare spending is on track to make up nearly 20% of U.S. GDP by 2025, according to the U.S. Centers for Medicare & Medicaid Services (CMS).
That’s one of the reasons we expect the biotech stock we’re showing you today to double in price by 2020.
Another catalyst for this top biotech stock is the aging baby boomer generation. There are currently 76.5 million....More>>>
Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began. In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector,....More>>>
Its been said of biotech that its the wild west of the investment world. There may be gold in the hills but you better have a good map and a keen eye to find it. One such company that is shimmering of late is Ventripoint Diagnostics (OTC: VPTDF), the Toronto, Ontario based developer of medical devices. With its new cardiac imaging device, the VMS Plus , Ventripoint is changing the way....More>>>
Last year, Gilead Sciences (NASDAQ:GILD) managed a feat that very few of its peers ever have (or probably ever will): It shed a staggering $40 billion in value without a single top-selling drug going off patent.
GILD Market Cap data by YCharts.
In fact, the biotech actually launched multiple new products last year, such as the HIV medsOdefsey and Descovy, along with the latest addition....More>>>
William Patalon III
In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.
The announcement caught my eye for several reasons…
This is premium content for Private Briefing subscribers only.
On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):
Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although....More>>>
On Monday, energy stocks soared, pushing the Dow Jones Industrial Average to within almost 180 points of the 20,000 mark. But declines in the financials offset the energy gains and left the industrials short of the mark despite a gain of 0.2% for the Dow.
The S&P 500 fell 0.1%, and the Nasdaq lost 0.6% due to a decline in the financial sector of 0.9% after five sessions in the black.....More>>>
Best Biotech ETF: The biotech sector has been greatly outperforming the broader markets over the past three months. In fact, the Nasdaq Biotechnology sector has climbed more than 14% since June, while the Dow is up just 2% in that time.
And we see those biotech gains continuing from here. That’s why we’re bringing readers the best biotech ETF to buy now.